3 Dec 2016 - 6 Dec 2016
San Diego, CA, USA
Striking results with the Kymab antibody KY1005, summarised in the abstract, will be presented at the American Society of Hematology 58th Annual Meeting and Exposition.
Kymab's KY1005 antibody reduces the activity of OX40L: it is thought that OX40L might be involved in a range of diseases in which inappropriate T-cell responses are directed towards a patient’s own tissues, including certain autoimmune diseases.
The abstract outlines the pivotal role that KY1005 plays in a novel, evidence-based strategy to control acute graft-versus-host disease, the first autoimmune disease in which the antibody has been tested.
The ASH annual meeting includes high-calibre science covering the full spectrum of malignant and non-malignant haematology in a programme designed to encourage networking and collaboration. The ASH meeting is internationally distinguished for its exploration of the latest research and clinical advances in the field through activities and educational programming relevant to the unique interests of practicing haematologists, scientists, educators and trainees from around the world.